Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA5A | P35218 | 2/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | CA6 | P23280 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | MDM4 | O15151 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9522207 | 0.97 | MAPT (0.62) | MAPTHDAC8CA1CA2CA9 | |
| SCHEMBL1158059 | 0.83 | CA12 (0.55) | MAPTHDAC8CA1CA2CA9 | |
| SCHEMBL1821914 | 0.81 | MAPT (0.68) | MAPTHDAC8CA1CA2CA9 | |
| Thiosalicylic Acid SCHEMBL31208541 | 0.79 | MAPT (1.00) | MAPTHDAC8CA1CA2CA9 | |
| Thiosalicylic Acid SCHEMBL28313023 | 0.79 | MAPT (1.00) | MAPTHDAC8CA1CA2CA9 | |
| Thiosalicylic Acid SCHEMBL50376 | 0.79 | MAPT (1.00) | MAPTHDAC8CA1CA2CA9 | |
| Thiosalicylic Acid SCHEMBL629705 | 0.79 | MAPT (1.00) | MAPTHDAC8CA1CA2CA9 | |
| SCHEMBL477978 | 0.77 | MAPT (0.62) | MAPTHDAC8CA1CA2CA9 | |
| SCHEMBL31475293 | 0.77 | MAPT (0.62) | MAPTHDAC8CA1CA2CA9 | |
| SCHEMBL1738490 | 0.77 | MAPT (0.70) | MAPTHDAC8CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2866777-A2 | REDUCING COMPOSITION COMPRISING AT LEAST ONE SULFUR-CONTAINING REDUCING AGENT, AT LEAST ONE FATTY SUBSTANCE, AT LEAST ONE CATIONIC SURFACTANT AND AT LEAST ONE OXYETHYLENATED NONIONIC SURFACTANT | L'OREAL (FR) | 2015-05-06 | — | — | EP | claimed |
| EP-2866778-A1 | REDUCING COMPOSITION COMPRISING AT LEAST ONE SULFUR-CONTAINING REDUCING AGENT, AT LEAST ONE FATTY SUBSTANCE, AT LEAST ONE CATIONIC SURFACTANT AND AT LEAST TWO POLYOXYALKYLENATED NONIONIC SURFACTANTS | L'OREAL (FR) | 2015-05-06 | — | — | EP | claimed |
| WO-2014001540-A2 | REDUCING COMPOSITION COMPRISING AT LEAST ONE SULFUR-CONTAINING REDUCING AGENT, AT LEAST ONE FATTY SUBSTANCE, AT LEAST ONE CATIONIC SURFACTANT AND AT LEAST ONE OXYETHYLENATED NONIONIC SURFACTANT | L'OREAL (FR) | 2014-01-03 | — | — | WO | claimed |
| WO-2014001542-A1 | REDUCING COMPOSITION COMPRISING AT LEAST ONE SULFUR-CONTAINING REDUCING AGENT, AT LEAST ONE FATTY SUBSTANCE, AT LEAST ONE CATIONIC SURFACTANT AND AT LEAST TWO POLYOXYALKYLENATED NONIONIC SURFACTANTS | L'OREAL (FR) | 2014-01-03 | — | — | WO | claimed |
| EP-1534690-A1 | 2-SUBSTITUTED BICYCLIC BENZOHETEROCYCLIC COMPOUNDS AND THEIR USE AS SODIUM CHANNEL BLOCKERS | Euro-Celtique S.A. (LU) | 2005-06-01 | — | — | EP | claimed |
| US-20040152696-A1 | 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers | EURO-CELTIQUE S.A. | 2004-08-05 | — | — | US | claimed |
| WO-2004013111-A1 | 2-SUBSTITUTED BICYCLIC BENZOHETEROCYCLIC COMPOUNDS AND THEIR USE AS SODIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2004-02-12 | — | — | WO | claimed |
| WO-2025034239-A1 | NATURAL FORMULATIONS TO REDUCE CPD LEVELS | YALE UNIVERSITY (US) | 2025-02-13 | — | — | WO | disclosed |
| US-11826355-B1 | Aspirin-mimetic antioxidants for treatment of age-related cataract | LU YANSONG (US) | 2023-11-28 | — | — | US | disclosed |
| US-11826355-B1 | Aspirin-mimetic antioxidants for treatment of age-related cataract | LU YANSONG (US) | 2023-11-28 | — | — | US | disclosed |
| EP-3873484-B1 | NOVEL STING AGONISTS | VENENUM BIODESIGN LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3707151-B1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICALS CO (JP) | 2022-01-05 | — | — | EP | disclosed |
| CN-113285024-A | Semiconductor device having quantum dots, display device, imaging system, and moving object | 佳能株式会社 | 2021-08-20 | — | — | CN | disclosed |
| EP-0945450-A1 | FUSED HETEROCYCLIC BENZENECARBOXYLIC ACID AMIDE DERIVATIVES AND PGD2 ANTAGONISTS CONTAINING THE SAME | SHIONOGI & CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
| US-5807813-A | Lubricating oil composition | IDEMITSU KOSAN CO., LTD. (JP) | 1998-09-15 | — | — | US | disclosed |
| EP-0859757-A1 | DERIVATES OF N,N-DIMETHYL-2-(ARYLTHIO)BENZYLAMINE, THEIR SALTS, METHODS OF PREPARATION AND THEIR USE IN PHARMACEUTICAL MEDICAMENTS | Farmak A.S. (CZ) | 1998-08-26 | — | — | EP | disclosed |
| EP-0783032-A1 | LUBRICATING OIL COMPOSITION | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1997-07-09 | — | — | EP | disclosed |
| WO-1997017325-A1 | DERIVATES OF N,N-DIMETHYL-2-(ARYLTHIO)BENZYLAMINE, THEIR SALTS, METHODS OF PREPARATION AND THEIR USE IN PHARMACEUTICAL MEDICAMENTS | FARMAK A.S. (CZ) | 1997-05-15 | — | — | WO | disclosed |
| EP-0422888-A2 | An electrophotographic lithographic printing plate precursor | FUJI PHOTO FILM CO., LTD. (JP) | 1991-04-17 | — | — | EP | disclosed |
| EP-0338808-A2 | Alkyl salicylate resin for carbonless copy paper and imaging use | SCHENECTADY INTERNATIONAL, INC. (US) | 1989-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152696-A1 | 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers | CACNA1C, CACNA1D, SCN2B | MAPT 1507/4885HDAC8 2110/4885CA1 411/4885 |
| US-11826355-B1 | Aspirin-mimetic antioxidants for treatment of age-related cataract | AGER, SOD3, CAT | MAPT 1162/4885HDAC8 2453/4885CA1 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.